Eli Lilly & Company (NYSE:LLY) has unveiled plans to introduce its weight-loss drug Mounjaro (tirzepatide) in new countries this year while simultaneously expanding manufacturing capacity,
The plans were revealed by Ilya Yuffa, President of Lilly International, Reuters noted, citing an interview at the World Economic Forum’s (WEF) annual meeting in Davos.
Negotiating reimbursement terms is a pivotal aspect for Lilly’s global expansion, according to Yuffa.
Also Read: Large Drugmakers Show Enthusiasm To Embrace $100B Obesity Market, Despite Novo And Lilly’s Dominance.
Despite Mounjaro’s approval in the U.S., the U.K., and ...